Vascular calcification and cardiovascular outcome in dialysis patients: The role of gene polymorphisms

Blood Purification

Volumn 29, Issue 4, 2010, Pages 347-351

  Cozzolino, Mario ^a   Biondi, Maria Luisa ^b   Galassi, Andrea ^a   Cusi, Daniele ^a,c   Brancaccio, Diego ^c   Gallieni, Maurizio ^d  

^a SAN PAOLO HOSPITAL   (Italy)

^b S Paolo Hospital   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d SAN CARLO BORROMEO HOSPITAL   (Italy)

Author keywords

Atherosclerosis; Gene polymorphism; Hemodialysis; Vascular calcification

Indexed keywords

CALCIUM; FETUIN A; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; OSTEOCALCIN; STROMELYSIN;

ARTERY CALCIFICATION; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CAROTID ARTERY OBSTRUCTION; CHRONIC KIDNEY DISEASE; CORONARY ARTERY; DIABETES MELLITUS; DISEASE ASSOCIATION; DNA POLYMORPHISM; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; METABOLIC DISORDER; MINERAL METABOLISM; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; REVIEW; RISK FACTOR; CALCINOSIS; CARDIOVASCULAR DISEASES; COMPLICATION; GENETIC POLYMORPHISM; GENETICS; PATHOLOGY; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY;

CALCINOSIS; CARDIOVASCULAR DISEASES; HUMANS; POLYMORPHISM, GENETIC; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 77950047534     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000302722     Document Type: Review

References (38)

1. Foley RN, Parfrey PS: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32(suppl 3): S112-S119. (Pubitemid 28527268)
2. Zoccali C, Tripepi G, Mallamaci F: Predictors of cardiovascular death in ESRD. Semin Nephrol 2005; 25: 358-362. (Pubitemid 41655967)
3. Longenecker JC, Coresh J, Powe NR, et al: Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE study. J Am Soc Nephrol 2002; 13: 1918-1927. (Pubitemid 34700618)
4. London GM: Cardiovascular calcifications in uremic patients: clinical impact on cardiovascular function. J Am Soc Nephrol 2003; 14:S305-S309. (Pubitemid 37052395)
5. Cozzolino M, Brancaccio D, Gallieni M, Slatopolsky E: Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 2005; 68: 429-436. (Pubitemid 43323098)
6. Cozzolino M, Mazzaferro S, Pugliese F, Brancaccio D: Vascular calcification and uremia: what do we know? Am J Nephrol 2008; 28: 339-346.
7. Stenvinkel, Ekstrom TJ: Epigenetics: a helpful tool to better understand processes in clinical nephrology? Nephrol Dial Transplant 2008; 23: 1493-1496.
8. Nordfors L, Lindholm B, Stenvinkel P: Endstage renal disease: not an equal opportunity disease: the role of genetic polymorphisms. J Int Med 2005; 258: 1-12. (Pubitemid 40904927)
9. Cozzolino M, Dusso AS, Slatopolsky E: Role of calcium-phosphate product and bone-associated proteins on vascular calcification in renal failure. J Am Soc Nephrol 2001; 12: 2511-2516. (Pubitemid 33021131)
10. Dollery CM, McEwan JR, Henney AM: Matrix metalloproteinases and cardiovascular disease. Circ Res 1995; 77: 863-878.
11. Cozzolino M, Biondi ML, Galassi A, et al: Matrix metalloproteinase-1 and matrix metalloproteinase-3 gene promoter polymorphisms are associated with mortality in haemodialysis patients. Nephrol Dial Transplant 2009; 24: 2207-2212.
12. Cozzolino M, Biondi ML, Galassi A, et al: Gene polymorphisms and serum alpha-2- Heremans-Schmid levels in Italian haemodialysis patients. Am J Nephrol 2007; 27: 639-642. (Pubitemid 350014951)
13. Brancaccio D, Biondi ML, Gallieni M, et al: Matrix GLA protein gene polymorphisms: clinical correlates and cardiovascular mortality in chronic kidney disease patients. Am J Nephrol 2005; 25: 548-552. (Pubitemid 41816049)
14. Nikkari ST, O'Brian KD, Ferguson M, et al: Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation 1995; 92: 1393-1398.
15. Ye S, Eriksson P, Hamsten A, et al: Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem 1996; 271: 13055-13060. (Pubitemid 26175880)
16. Ghilardi G, Biondi ML, DeMonti M, et al: Matrix metalloproteinase-1 and matrix metalloproteinase-3 gene promoter polymorphisms are associated with carotid artery stenosis. Stroke 2002; 33: 2408-2412.
17. Newby AC, Johnson JL: Genetic strategies to elucidate the roles of matrix metalloproteinases in atherosclerotic plaque growth and stability. Circ Res 2005; 97: 958-960.
18. Abilleira S, Bevan S, Markus HS: The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclerosis. J Med Genet 2006; 43: 897-901. (Pubitemid 46080185)
19. Humphries SE, Luong LA, Talmud PJ, et al: The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Lopid Coronary Angiography Trial. Atherosclerosis 1998; 139: 49-56.
20. Libby P: Molecular bases of the acute coronary syndromes. Circulation 1995; 91: 2844-2850.
21. Pollanen PJ, Lehtimaki T, Ilveskoski E, et al: Coronary artery calcification is related to functional polymorphism of matrix metalloproteinase 3. The Helsinki Sudden Death Study. Atherosclerosis 2002; 164: 329-335. (Pubitemid 35223084)
22. Gnasso A, Motti C, Irace C, et al: Genetic variation in human stromelysin gene promoter and common carotid geometry in healthy male subjects. Arterioscler Thromb Vasc Biol 2000; 20: 1600-1605. (Pubitemid 30353894)
23. Lehrke M, Greif M, Broedl UC, et al: MMP-1 serum levels predict coronary atherosclerosis in humans. Cardiovasc Diabet 2009; 8: 50.
24. 2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. J Biol Chem 1996; 271: 20789-20796.
25. 2 Heremans-Schmid glycoprotein/ fetuin A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003; 112: 357-366. (Pubitemid 38063764)
26. Ketteler M, Bongartz P, Westenfeld R, et al: Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361: 827-833. (Pubitemid 36331846)
27. Cozzolino M, Galassi A, Biondi ML, et al: Serum fetuin-A levels link inflammation and cardiovascular calcification in haemodialysis patients. Am J Nephrol 2006; 26: 423-429. (Pubitemid 44971732)
28. Stenvinkel P, Wang K, Qureshi AR, et al: Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin. Kidney Int 2005; 67: 2383-2392. (Pubitemid 41623401)
29. Lehtinen AB, Burdon KP, Lewis JP, et al: Association of alpha2-Heremans-Schmid glycoprotein polymorphisms with subclinical atherosclerosis. J Clin Endocrinol Metab 2007; 92: 345-352. (Pubitemid 46075012)
30. Geroldi D, Minoretti P, Bianchi M, et al: Genetic association of alpha2-Heremans- Schmid glycoprotein polymorphism with late-onset Alzheimer's disease in Italians. Neurosci Lett 2005; 386: 176-178. (Pubitemid 41112309)
31. Russo D, Corrao S, Mirando I, et al: Progression of coronary artery calcification in predialysis patients. Am J Nephrol 2007; 27: 152-158. (Pubitemid 46588180)
32. Mazzaferro S, Pasquali M, Pugliese F, et al: Serum levels of calcification inhibition proteins and coronary artery calcium score: comparison between transplantation and dialysis. Am J Nephrol 2007; 27: 75-83. (Pubitemid 46364544)
33. Luo G, Ducy P, McKee MD, et al: Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386: 78-81. (Pubitemid 27130923)
34. Shanahan CM, Cary NR, Metcalfe LC, Weissberg PL: High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. Clin Invest 1994; 93: 2393-2402.
35. Herrmann SM, Whatling C, Brand E, et al: Polymorphisms of the human matrix GLA protein (MGP) gene, vascular calcification and myocardial infarction. Arterioscler Thromb Vasc Biol 2000; 20: 2386-2393.
36. Farzaneh-Far A, Davies JD, Braam LA, et al: A polymorphism of the human matrix γ- carboxyglutamic acid protein promoter alters binding of an activating protein-1 complex and is associated with altered transcription and serum levels. J Biol Chem 2001; 276: 32466-32473. (Pubitemid 37384683)
37. Wang K, Honda H, Qureshi AR, et al: Association between the matrix GLA protein-7 polymorphism and carotid intima-media area and left ventricular hypertrophy in endstage renal disease patients. ERA-EDTA XLI Congr, May 2004, Lisbon.
38. Wang K, Honda H, Qureshi AR, et al: The matrix GLA protein-138 genotype is associated with clinical outcome in end-stage renal disease patients. ERA-EDTA XLI Congr, May 2004, Lisbon.